Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735371 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
NCT00735371 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 314 participants.
The verdict
NCT00735371, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
Interventions
- DRUG Placebo
- DRUG LDX 30 mg
- DRUG LDX 50 mg
- DRUG LDX 70 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2008-10-08 |
| Est. Completion | 2009-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735371
The ClinicalTrials.gov registry entry for NCT00735371 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00735371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735371 about?
NCT00735371 is a clinical study titled "Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)". The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
What is the current status of trial NCT00735371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2008-10-08. Estimated completion is 2009-04-06.
What interventions are being tested in trial NCT00735371?
The interventions under investigation include: Placebo (DRUG), LDX 30 mg (DRUG), LDX 50 mg (DRUG), LDX 70 mg (DRUG).
Who is sponsoring clinical trial NCT00735371?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.